In Egypt, type 2 Diabetes Mellitus is managed by endocrinologists. Type 2 diabetes mellitus is a metabolic disease driven by progressive insulin resistance and beta-cell dysfunction that leaves blood glucose persistently elevated. It affects roughly 38.4 million Americans (11.6% of the adult population, CDC 2024) and more than 537 million adults globally (IDF Atlas 10th edition), with prevalence rising fastest in South and East Asia.
Type 2 diabetes mellitus (ICD-10: E11) is a chronic disorder of glucose homeostasis defined by insulin resistance in liver, skeletal muscle, and adipose tissue combined with progressive failure of pancreatic beta cells to compensate. The American Diabetes Association 2024 Standards of Care diagnose diabetes when any of the following is confirmed on two occasions or paired with classical symptoms: fasting plasma glucose ≥126 mg/dL (7.0 mmol/L), 2-hour plasma glucose ≥200 mg/dL (11.1 mmol/L) on a 75-gram oral glucose tolerance test, HbA1c ≥6.5% (48 mmol/mol), or a random plasma glucose ≥200 mg/dL with classical symptoms of hyperglycemia. The disease intersects three organ axes simultaneously — atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease — and is now framed by the ADA and EASD as a cardio-renal-metabolic syndrome rather than a glucose-centric disease. Management is delivered by endocrinologists, primary care physicians, diabetes specialist nurses, dietitians, podiatrists, and ophthalmologists in coordinated programs..
The key symptoms of Type 2 Diabetes Mellitus are: Increased thirst and frequent urination, especially overnight, occurring once blood glucose exceeds the renal threshold of roughly 180 mg/dL (10 mmol/L)., Unexplained fatigue and reduced exercise tolerance, often present months before diagnosis as cells fail to take up glucose efficiently., Slow wound healing and recurrent skin infections — small cuts on the feet or hands persist for weeks rather than days., Blurred vision from osmotic shifts in the lens, fluctuating with glucose levels and often resolving with treatment., Recurrent vaginal or balanitis fungal infections driven by glucose in skin and mucosal secretions., Unintended weight loss of 5-10% over 3-6 months in a minority of patients, especially when glucose is markedly elevated., Numbness, tingling, or burning in the feet that worsens at night — early diabetic peripheral neuropathy can predate diagnosis by years..
Diagnosis follows the 2024 ADA Standards of Care. Type 2 diabetes is established by any of: fasting plasma glucose ≥126 mg/dL (7.0 mmol/L), 2-hour plasma glucose ≥200 mg/dL on a 75-gram oral glucose tolerance test, HbA1c ≥6.5% (48 mmol/mol), or a random plasma glucose ≥200 mg/dL with classical hyperglycemic symptoms. A single random plasma glucose ≥200 mg/dL with symptoms is diagnostic; all other criteria require confirmation on a separate day. HbA1c is the preferred test for asymptomatic screening because it does not require fasting, captures average glucose over 8-12 weeks, and predicts microvascular complications well. HbA1c is unreliable in hemoglobinopathies, hemolysis, recent transfusion, and severe iron deficiency — in these settings, fasting glucose or oral glucose tolerance testing is preferred. Initial workup at diagnosis includes lipid panel, urine albumin-to-creatinine ratio, serum creatinine with eGFR, liver function tests, dilated fundus examination by ophthalmology, comprehensive foot examination including monofilament and vibration testing, blood pressure, and cardiovascular risk assessment. Antibody testing (GAD, IA-2, ZnT8) is reserved for atypical presentations — lean adults, rapid progression to insulin requirement, or strong personal or family history of autoimmunity — to detect latent autoimmune diabetes in adults. C-peptide measurement helps distinguish residual beta-cell function in unclear cases. Screening adults from age 35 every 3 years, or earlier with risk factors, is recommended.
With contemporary therapy, the prognosis of type 2 diabetes has improved substantially. Maintaining HbA1c under 7%, blood pressure under 130/80 mmHg, and LDL under 70 mg/dL with appropriate ACE inhibitor or ARB, statin, and SGLT2 inhibitor or GLP-1 agonist therapy reduces cardiovascular events by 50% versus standard care (Steno-2 trial). Recently diagnosed patients who achieve and sustain substantial weight loss can enter diabetes remission — 46% at one year and 36% at two years in the DiRECT trial. Without treatment, type 2 diabetes doubles cardiovascular mortality, causes 44% of new chronic kidney disease, and is the leading cause of adult blindness and non-traumatic lower-limb amputation. Median life expectancy is reduced by 4-6 years in middle-aged adults at diagnosis, narrowing substantially with modern multifactorial care. The decisive prognostic factors are early intensive treatment, sustained weight management, smoking status, and adherence to long-term cardiovascular-protective therapy.
An endocrinologist or diabetologist should be involved when HbA1c remains above target despite metformin plus two additional agents, when insulin is being initiated or titrated, when complications such as diabetic kidney disease, severe neuropathy, or recurrent hypoglycemia emerge, in suspected LADA or unusual phenotypes, in pregnancy or pre-pregnancy counseling, and when bariatric or metabolic surgery is being considered. Primary care manages most uncomplicated type 2 diabetes effectively if treat-to-target is followed.
Find specialists →Glycemic improvement begins within 1-2 weeks of metformin or lifestyle change; full HbA1c response is seen at 3 months. Weight loss with GLP-1 agonists plateaus at 12-18 months. Diabetic retinopathy and nephropathy progression is measurably slowed within 1-2 years of tight glycemic and blood pressure control. Remission from intensive weight loss is most likely within 6 years of diagnosis; the longer the disease duration, the lower the remission probability.
Aim for 150-300 minutes weekly of moderate-intensity aerobic activity spread over at least three days, with no more than two consecutive days without exercise. Add 2-3 resistance training sessions weekly targeting major muscle groups. Break up prolonged sitting every 30 minutes with light activity. Patients on insulin or sulfonylureas should monitor glucose around exercise and have rapid carbohydrate available.
Look for endocrinology board certification, structured diabetes education programs at the practice (registered dietitians, diabetes educators, podiatry), access to continuous glucose monitoring and insulin-pump training, comfort with newer GLP-1 and SGLT2 regimens, and integrated care for cardiovascular and renal complications. Continuity matters more than prestige — diabetes management is a multi-decade relationship.
Medically reviewed by AIHealz Medical Editorial Board · May 13, 2026
Ranked by patient outcomes and specialized experience.
Verifying top specialists in Egypt.
Apply as specialist →Specialists who treat Type 2 Diabetes Mellitus. Get expert guidance and personalized care.